目的:研究宫颈腺癌1p31杂合性丢失的发生率,探讨在此位点的ARHI基因在宫颈腺癌发生发展中的作用。方法:采用PCR银染技术检测30例宫颈腺癌中1p31杂合性丢失的发生率,其中Ⅰ,Ⅱ期18例,Ⅲ、Ⅳ期12例,免疫组化方法检测在此位点的ARHI蛋白的表达。结果:30例宫颈腺癌组织中LOH阳性的比例为63.33%(19/30),Ⅲ期、Ⅳ期LOH阳性率明显高于Ⅰ,Ⅱ期,差异有统计学意义(χ2=5.98,P<0.05)。在高、中、低分化癌中无统计学差异(χ2=4.88,P>0.05),ARHI蛋白的阳性表达率与淋巴结转移无关,差异无统计学意义(χ2=2.16,P>0.05)。宫颈腺癌组织中ARHI表达(46.67%,14/30)低于正常宫颈组织(90.0%,27/30),差异具有统计学意义(χ2=13.02,P<0.05)。结论:1p31位点可能存在宫颈腺癌相关抑癌基因,ARHI基因在宫颈腺癌发生发展过程中起重要作用。 Objective: To study the incidence of loss of heterozygosity of 1p31 in cervical adenocarcinoma and to explore the role of ARHI gene in the development of cervical adenocarcinoma. Methods: PCR-silver staining was used to detect the loss of 1p31 heterozygosity in 30 cases of cervical adenocarcinoma. Among them, 18 cases were stage Ⅰ and Ⅱ, 12 cases were stage Ⅲ and Ⅳ. The ARHI protein in this site was detected by immunohistochemistry expression. Results: The positive rate of LOH in 30 cases of cervical adenocarcinoma was 63.33% (19/30). The positive rates of LOH in stage Ⅲ and stage Ⅳ were significantly higher than those in stage Ⅰ and Ⅱ, the difference was statistically significant (χ2 = 5.98, P < 0.05). There was no significant difference in high, moderate, and poorly differentiated carcinoma (χ2 = 4.88, P> 0.05). The positive expression rate of ARHI protein was not related to lymph node metastasis (χ2 = 2.16, P> 0.05). The expression of ARHI in cervical adenocarcinoma was lower than that in normal cervical tissue (46.67%, 14/30) (90.0%, 27/30). The difference was statistically significant (χ2 = 13.02, P <0.05). Conclusion: The 1p31 site may exist cervical adenocarcinoma related tumor suppressor gene, ARHI gene plays an important role in the development of cervical adenocarcinoma.